Christina Guttmann-Gruber

Christina Guttmann-Gruber is a Researcher at the Department of Dermatology and Allergology, Faculty of Medicine, Paracelsus Medical University. She leads the Research Program for Molecular Therapy in Genodermatoses and has established herself as a prominent researcher in the field of rare skin disorders, particularly epidermolysis bullosa.

Her research interests span across dermatology, molecular therapy, gene editing, skin cancer research, wound healing, drug repositioning, transcriptomics, stem cell research, and antisense therapy. She has focused extensively on epidermolysis bullosa, investigating molecular mechanisms, developing therapeutic approaches, and studying complications such as squamous cell carcinoma development in these patients.

Analysis of her recent publications reveals a strong focus on innovative therapeutic strategies for epidermolysis bullosa, including gene editing techniques, antisense oligonucleotide therapies, drug repositioning approaches, and stem cell-based models. Her work bridges basic molecular research with clinical applications, aiming to translate scientific discoveries into tangible treatments for patients with rare skin disorders.

• Anton Luger Dissertations Preis (2009)
• Isidor Neumann Poster Preis (2011)
• Wissenschaftspreis in Bronze 2010 (2011)
• Non-Melanoma Skin Cancer Forschungspreis der Firma MEDA Pharma (2013)
• Sanofi Preis (2014)

Dr. Guttmann-Gruber has successfully led multiple research projects focusing on epidermolysis bullosa, including investigations into wound healing mechanisms, squamous cell carcinoma development, and bacterial contributions to disease progression. She serves as a peer reviewer for prominent journals including PLOS ONE and NEOPLASIA, contributing to the scientific community through editorial activities. Her research program represents a comprehensive approach to understanding and treating genodermatoses, with particular emphasis on molecular therapeutic interventions.